The effect of C1 inhibitor on intestinal ischemia and reperfusion injury

American Journal of Physiology - Gastrointestinal and Liver Physiology

Volumn 295, Issue 5, 2008, Pages

  Lu, Fengxin ^a,b   Chauhan, Anil K ^a   Fernandes, Stacey M ^a   Walsh, Meghan T ^a   Wagner, Denisa D ^a   Davis III, Alvin E ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b CENTER FOR BLOOD RESEARCH   (United States)

Author keywords

Complement inhibition; Leukocyte transmigration

Indexed keywords

COMPLEMENT COMPONENT C1S INHIBITOR; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CONTROLLED STUDY; INTESTINE INJURY; INTESTINE ISCHEMIA; LEUKOCYTE; MESENTERY BLOOD FLOW; MOUSE; NEUTROPHIL CHEMOTAXIS; NONHUMAN; PRIORITY JOURNAL; REPERFUSION INJURY; SUPERIOR MESENTERIC ARTERY OBSTRUCTION; SURVIVAL RATE;

ANIMALS; COMPLEMENT C1 INHIBITOR PROTEIN; COMPLEMENT C3; GENE EXPRESSION REGULATION; GRANULOCYTE COLONY STIMULATING FACTOR, RECOMBINANT; INTERLEUKIN-3; INTESTINAL MUCOSA; INTESTINES; L-LACTATE DEHYDROGENASE; LEUKOCYTES; MESENTERY; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; RECEPTOR, BRADYKININ B2; RECOMBINANT FUSION PROTEINS; REPERFUSION INJURY; TUMOR NECROSIS FACTOR-ALPHA;

EID: 57349163110     PISSN: 01931857     EISSN: 15221547     Source Type: Journal    
DOI: 10.1152/ajpgi.90460.2008     Document Type: Article

References (52)

1. Arakawa K, Takeyoshi I, Akao Y, Totsuka O, Matsumoto K, Morishita Y. Bradykinin B2 receptor antagonist FR173657 ameliorates small bowel ischemia-reperfusion injury in dogs. Dig Dis Sci 50: 27-36, 2005.
2. Arumugam TV, Magnus T, Woodruff TM, Proctor LM, Shiels IA, Taylor SM. Complement mediators in ischemia-reperfusion injury. Clin Chim Acta 374: 33-45, 2006.
3. Aulak KS, Harrison RA. Rapid and sensitive techniques for identification and analysis of 'reactive-centre' mutants of C1-inhibitor proteins contained in type II hereditary angio-oedema plasmas. Biochem J 271: 565-569, 1990.
4. Buerke M, Murohara T, Lefer AM. Cardioprotective effects of a C1 esterase inhibitor in myocardial ischemia and reperfusion. Circulation 91: 393-402, 1995.
5. Cai S, Davis AE 3rd. Complement regulatory protein C1 inhibitor binds to selectins and interferes with endothelial-leukocyte adhesion. J Immunol 171: 4786-4791, 2003.
6. Cai S, Dole V, Bergmeier W, Scafidi J, Feng H, Wagner DD, Davis AE 3rd. A direct role for C1 inhibitor in leukocyte adhesion. J Immunol 174: 6462-6466, 2005.
7. Caliezi C, Wuillemin WA, Zeerleder S, Redondo M, Eisele B, Hack CE. C1-esterase inhibitor: an anti-inflammatory agent and its potential use in the treatment of diseases other than hereditary angioedema. Pharmacol Rev 52: 91-112, 2001.
8. Carden DL, Granger DN. Pathophysiology of ischemia-reperfusion injury. J Pathol 190: 255-266, 2000.
9. Cerqueira NF, Hussni CA, Yoshida WB. Pathophysiology of mesenteric ischemia/reperfusion. Acta Cir Bras 20: 336-343, 2005.
10. Chauhan AK, Kisucka J, Brill A, Walsh MT, Scheiflinger F, Wagner DD. ADAMTS13: a new link between thrombosis and inflammation. J Exp Med 205: 2065-2074, 2008.
11. Chiu CJ, McArdle AH, Brown R, Scott HJ, Gurd FN. Intestinal mucosal lesion in low-flow states. I. A morphological, hemodynamic, and metabolic reappraisal. Arch Surg 101: 478-483, 1970.
12. Davis AE 3rd. Biological effects of C1 inhibitor. Drug News Perspect 17: 439-446, 2004.
13. de Zwaan C, Kleine AH, Diris JH, Glatz JF, Wellens HJ, Strengers PF, Tissings M, Hack CE, van Dieijen-Visser MP, Hermens WT. Continuous 48-h C1-inhibitor treatment, following reperfusion therapy, in patients with acute myocardial infarction. Eur Heart J 23: 1670-1677, 2002.
14. Eror AT, Stojadinovic A, Starnes BW, Makrides SC, Tsokos GC, Shea-Donohue T. Antiinflammatory effects of soluble complement receptor type 1 promote rapid recovery of ischemia/reperfusion injury in rat small intestine. Clin Immunol 90: 266-275, 1999.
15. Farmer DG, Anselmo D, Shen XD, Ke B, Carmody IC, Gao F, Lassman C, McDiarmid SV, Shaw G, Busuttil RW, Kupiec-Weglinski JW. Disruption of P-selectin signaling modulates cell trafficking and results in improved outcomes after mouse warm intestinal ischemia and reperfusion. Transplantation 80: 828-835, 2005.
16. Grisham MB, Hernandez LA, Granger LA. Xanthine oxidase and neutrophil infiltration in intestinal ischemia. Am J Physiol Gastrointest Liver Physiol 251: G567-G574, 1986.
17. Grotz M, Regel G, Schratt HE, Seekamp A, Pape HC, Tscherne H. Intestinal cytokine liberation after intestinal ischemia in the rat-studies in the Ussing chamber system. Z Gastroenterol 34: 783-790, 1996.
18. Grotz MR, Deitch EA, Ding J, Xu D, Huang Q, Regel G. Intestinal cytokine response after gut ischemia: role of gut barrier failure. Ann Surg 229: 478-486, 1999.
19. Han ED, MacFarlane RC, Mulligan AN, Scafidi J, Davis AE 3rd. Increased vascular permeability in C1 inhibitor-deficient mice is mediated by the bradykinin type 2 receptor. J Clin Invest 109: 1057-1063, 2002.
20. Hattori R, Hamilton KK, McEver RP, Sims PJ. Complement proteins C5b-9 induce secretion of high molecular weight multimers of endothelial von Willebrand factor and translocation of granule membrane protein GMP-140 to the cell surface. J Biol Chem 264: 9053-9060, 1989.
21. Hill JH, Ward PA. The phlogistic role of C3 leukotactic fragments in myocardial infarcts of rats. J Exp Med 133: 885-900, 1971.
22. Homer-Vanniasinkam S, Crinnion JN, Gough MJ. Post-ischaemic organ dysfunction: a review. Eur J Vasc Endovasc Surg 14: 195-203, 1997.
23. Horie Y, Ishii H. Liver dysfunction elicited by gut ischemia-reperfusion. Pathophysiology 8: 11-20, 2001.
24. Horstick G, Kempf T, Lauterbach M, Bhakdi S, Kopacz L, Heimann A, Malzahn M, Horstick M, Meyer J, Kempski O. C1 inhibitor treatment at early reperfusion of hemorrhagic shock reduces mesentery leukocyte adhesion and rolling. Microcirculation 8: 427-433, 2001.
25. Jaeschke H, Farhood A, Bautista AP, Spolarics Z, Spitzer JJ. Complement activates Kupffer cells and neutrophils during reperfusion after hepatic ischemia. Am J Physiol Gastrointest Liver Physiol 264: G801-G809, 1993.
26. Jiang H, Wagner E, Zhang H, Frank MM. Complement 1 inhibitor is a regulator of the alternative complement pathway. J Exp Med 194: 1609-1616, 2001.
27. Kakoki M, McGarrah RW, Kim HS, Smithies O. Bradykinin B1 and B2 receptors both have protective roles in renal ischemia/reperfusion injury. Proc Natl Acad Sci USA 104: 7576-7581, 2007.
28. Karpel-Massler G, Fleming SD, Kirschfink M, Tsokos GC. Human C1 esterase inhibitor attenuates murine mesenteric ischemia/reperfusion induced local organ injury. J Surg Res 115: 247-256, 2003.
29. Kilgore KS, Ward PA, Warren JS. Neutrophil adhesion to human endothelial cells is induced by the membrane attack complex: the roles of P-selectin and platelet activating factor. Inflammation 22: 583-598, 1998.
30. Kirschfink M, Nurnberger W. C1 inhibitor in anti-inflammatory therapy: from animal experiment to clinical application. Mol Immunol 36: 225-232, 1999.
31. Lauterbach M, Horstick G, Plum N, Lotz J, Lauterbach E, Weilemann LS, Kempski O. C1-esterase inhibitor reverses functional consequences of superior mesenteric artery ischemia/reperfusion by limiting reperfusion injury and restoring microcirculatory perfusion. Shock 27: 75-83, 2007.
32. Lefer AM, Lefer DJ. Pharmacology of the endothelium in ischemia-reperfusion and circulatory shock. Annu Rev Pharmacol Toxicol 33: 71-90, 1993.
33. Lehmann TG, Heger M, Munch S, Kirschfink M, Klar E. In vivo microscopy reveals that complement inhibition by C1-esterase inhibitor reduces ischemia/reperfusion injury in the liver. Transpl Int 13, Suppl 1: S547-S550, 2000.
34. Leister I, Mbachu EM, Post S, Samel MM, Stojanovic T, Gutt CN, Becker H, Markus PM. Vasoactive intestinal polypeptide and gastrin-releasing peptide attenuate hepatic microvasculatory disturbances following intestinal ischemia and reperfusion. Digestion 66: 186-192, 2002.
35. Liu D, Cai S, Gu X, Scafidi J, Wu X, Davis AE 3rd. C1 inhibitor prevents endotoxin shock via a direct interaction with lipopolysaccharide. J Immunol 171: 2594-2601, 2003.
36. Panes J, Granger DN. Leukocyte-endothelial cell interactions: molecular mechanisms and implications in gastrointestinal disease. Gastroenterology 114: 1066-1090, 1998.
37. Pemberton PA, Harrison RA, Lachmann PJ, Carrell RW. The structural basis for neutrophil inactivation of C1 inhibitor. Biochem J 258: 193-198, 1989.
38. Petersen SV, Thiel S, Jensen L, Vorup-Jensen T, Koch C, Jensenius JC. Control of the classical and the MBL pathway of complement activation. Mol Immunol 37: 803-811, 2000.
39. Pierro A, Eaton S. Intestinal ischemia reperfusion injury and multisystem organ failure. Semin Pediatr Surg 13: 11-17, 2004.
40. Ratnoff O, Lepow I. Some properties of an esterase derived from preparations of the first component of complement. J Exp Med 106: 327-343, 1957.
41. Rehrig S, Fleming SD, Anderson J, Guthridge JM, Rakstang JE, McQueen C, Holers VM, Tsokos GC, Shea-Donohue T. Complement inhibitor, complement receptor 1-related gene/protein y-Ig attenuates intestinal damage after the onset of mesenteric ischemia/reperfusion injury in mice. J Immunol 167: 5921-5927, 2001.
42. Riedemann NC, Ward PA. Complement in ischemia reperfusion injury. Am J Pathol 162: 363-367, 2003.
43. Schmidt W, Stenzel Z, Gebhard MM, Martin E, Schmidt H. C1-esterase inhibitor and its effects on endotoxin-induced leukocyte adherence and plasma extravasation in postcapillary venules. Surgery 125: 280-287, 1999.
44. Sim RB, Reboul A, Arlaud GJ, Villiers CL, Colomb MG. Interaction of 125I-labelled complement components C1r and C1s with protease inhibitors in plasma. FEBS Lett 97: 111-115, 1979.
45. Souza DG, Coutinho SF, Silveria MR, Cara DC, Teixeira MM. Effects of a BLT receptor antagonist on local and remote reperfusion injuries after transit ischemia of the superior mesenteric artery in rats. Eur J Pharmacol 403: 121-128, 2000.
46. Souza DG, Lomez ES, Pinho V, Perquero JB, Bader M, Perquero JL, Teixeira MM. Role of bradykinin B2 and B1 receptors in the local, remote and systemic inflammatory responses that follow intestinal ischemia and reperfusion injury. J Immunol 172: 2452-2458, 2004.
47. Souza DG, Teixeira MM. The balance between the production of tumor necrosis factor-alpha and interleukin-10 determines tissue injury and lethality during intestinal ischemia and reperfusion. Mem Inst Oswaldo Cruz 100, Suppl 1: 59-66, 2005.
48. Williams JP, Pechet TT, Weiser MR, Reid R, Kobzik L, Moore FD Jr, Carroll MC, Hechtman HB. Intestinal reperfusion injury is mediated by IgM and complement. J Appl Physiol 86: 938-942, 1999.
49. Wong NKH, Kojima M, Dobo J, Ambrus G, Sim RB. Activities of the MBL-associated serine proteases (MASPs) and their regulation by natural inhibitors. Mol Immunol 36: 853-861, 1999.
50. Xia CF, Smith RS, Shen B, Yang ZR, Borlongan CV, Chao L, Chao J. Postischemia brain injury is exacerbated in mice lacking the kinin B2 receptor. Hypertension 47: 752-761, 2006.
51. Yamamoto S, Tanabe M, Wakabayashi G, Shimuzu M, Matsumoto K, Kitajima M. The role of tumor necrosis factor-alpha and interleukin-1 beta in ischemia-reperfusion injury of the rat small intestine. J Surg Res 99: 134-141, 2001.
52. Ziccardi RJ. Activation of the early components of the classical complement pathway under physiological conditions. J Immunol 126: 1768-1773, 1981.